Latest: AVM Biotechnology interviewed by KOMO 4 News - AVM0703 expected to be more effective than Oxford's trial results! Watch now!

Global problems demand global solutions

Mechanism of Action
Future Pandemics


“Drugs such as AVM0703 that mobilise endogenous supercharged natural killer cells, cytotoxic T cells and dendritic cells provide a potential solution for the treatment of seriously ill COVID19 patients, are available, have safety data, and are registered for the treatment of other diseases. It is in this area that large scale studies should be undertaken as they can be used to immediately treat patients together with other interventions. Such drugs are also potentially useful in other infectious disease settings where vaccines and antiviral drugs are ineffective or unavailable. ” 


– Dr. Gary Grohmann


Former Director of Immunobiology and the WHO ERL at the TGA; Director of the Immunisation Coalition; Director and Founder of Environmental Pathogens; and former WHO Advisor and Consultant

AVM0703 has FDA approval to proceed with clinical trials in COVID-19 and ARDS